Clinical Trials Logo

Clinical Trial Summary

Primary knee arthroplasty by total prosthesis is a painful surgery, performed on patients with advanced gonarthrosis (stage III), thus already presenting hyperalgesia and hyperalgesia and allodynia. This terrain makes the risk of postoperative hyperalgesia but also of persistent postoperative risk of persistent post-surgical pain. Nefopam is a non-opioid centrally acting analgesic drug used as a part of multimodal analgesia. The opioid-sparing effect of nefopam is still controversial across various surgical procedures. In France nefopam is only available as a parenteral formulation; however it is often administered orally. There is currently no study addressing the efficacy of oral nefopam for the postoperative pain management including pain prevention. The investigators conduct a prospective, double-blinded randomized controlled study with the main objective to examine the effect of perioperative orally administered nefopam on postoperative pain after a total knee arthroplasty. Secondary objectives include the quantification of wound allodynia, analysis of adverse events, clinical outcomes, and a pharmacokinetic study of orally given nefopam (plasma and cerebrospinal fluid dosage).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04576078
Study type Interventional
Source Hospices Civils de Lyon
Contact Frederic AUBRUN, MD/PHD
Phone 4 72 07 26 11
Email Frederic.aubrun@chu-lyon.fr
Status Recruiting
Phase Phase 2
Start date June 29, 2021
Completion date November 15, 2026